ЛИМ Се Ёнг (KR),ПАРК Сан Хи (KR),СХИН Рюнг Ае (KR),ЧХОЙ Ин Юнг (KR),КВОН Се Чан (KR)
申请号：
RU2014133615
公开号：
RU2014133615A
申请日:
2013.03.08
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease, comprising as an active ingredient an insulinotropic peptide drug conjugate obtained by covalently linking an insulinotropic peptide and an immunoglobulin Fc fragment using a non-peptidyl polymer, wherein the insulinotropic peptide is selected from the group consisting of exendin-4, exendin-4 derivative obtained by removing the N-terminal amino group of exendin-4； exendin-4 derivative obtained by replacing the N-terminal exendin-4 amino group per hydroxyl group of exendin-4 derivative obtained by modifying the N-terminal amino group of exendin-4 with a dimethyl group and exendin-4 derivative obtained by removing the alpha-carbon of the N-terminal residue of exendin-4 histidine and N- the terminal amino group bonded to alpha carbon, and the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymers, polyoxyethylene polyols, polyvinyl alcohol, polysaccharide ides, dextran, polyvinyl ethyl ether, biodegradable polymers, polymers of lipids, chitins, hyaluronic acid and their combinations. 2. The pharmaceutical composition of claim 1, wherein the non-peptidyl polymer is coupled to an amino acid residue that is not an N-terminal residue of an insulinotropic peptide. The pharmaceutical composition of claim 1, wherein the immunoglobulin Fc fragment and the amino group or thiol group of the insulinotropic peptide are attached to both ends of the non-peptidyl polymer, respectively. The pharmaceutical composition of claim 1, wherein the non-peptidyl polymer with1. Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой болезни печени, содержащая в качестве активного ингредиента лекарственный конъюгат инсулинотропного пептида, полученный ковалентным связыванием инсулинотропного пептида и Fc-фрагмента иммуноглобулина посредством непептидильного полимера, где инсулин
